Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins.
Saved in:
| Title: | Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins. |
|---|---|
| Authors: | Butt N; Department of Cardiology, Stavanger University Hospital, Stavanger, Norway., Bache-Mathiesen LK, Nordrehaug JE, Tuseth V, Munk PS, Bonarjee V, Hall TS, Jensen SE, Halvorsen S, Firat H, Atar D, Larsen AI |
| Source: | Cardiology [Cardiology] 2017; Vol. 138 (2), pp. 122-132. Date of Electronic Publication: 2017 Jun 27. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Karger Country of Publication: Switzerland NLM ID: 1266406 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9751 (Electronic) Linking ISSN: 00086312 NLM ISO Abbreviation: Cardiology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1421-9751 |
|---|---|
| DOI: | 10.1159/000475460 |
